HM PharmaConsultancy

H.M. Pharma Consultancy - The Life Science Knowledge Foundry - advises on drug development, repurposing, and patenting. Mastodon: @[email protected]

[HM PharmaConsultancy @hmpharmacon]

How AI can help find new uses for the drugs we have https://t.co/ogylMPc0q3

[HM PharmaConsultancy @hmpharmacon]

Hermann Mucke will present "RepoScope: An AI-supported database to build a navigable network of drug repurposing prior art" at #RExPO25. A first for a broad audience! - https://t.co/wSt9E9kruZ

[HM PharmaConsultancy @hmpharmacon]

New journal at #ScienceOpen: Network and Systems Medicine https://t.co/wVJcr6y7t5 The first papers: https://t.co/fPorHWodrx) and https://t.co/L0StE45cmG

[HM PharmaConsultancy @hmpharmacon]

'International Drug Repurposing Patent Landscape, Part 3: Chronic Neurodegenerative Diseases 2010-2024' an article on #ScienceOpen: https://t.co/RscAmaVovX

[HM PharmaConsultancy @hmpharmacon]

International Drug Repurposing Patent Landscape, Part 3: Chronic Neurodegenerative Diseases 2010-2024 DrugRxiv DOI: https://t.co/z5x0wrT2xJ

[HM PharmaConsultancy @hmpharmacon]

@cdsouthan All show some processed data. Open Data as per definition is something you will hardly find in a patent application, although the assignee has to show the examiner the raw data on request.

[concentris @concentris_EU]

🎄With our Christmas Newsletter🌟, we wish you a wonderful holiday season & a happy + healthy new year:
https://t.co/0eEcO1RdbK
See you again in 2025😊
#ProposalWriting #ScienceCommunication #ProjectManagement #ConferenceServices
@HorizonEU @ERC_Research @BMBF_Bund @dfg_public

[HM PharmaConsultancy @hmpharmacon]

"International #DrugRepurposing #Patent Landscaping, Part 2: The Early Months of #Covid19 https://t.co/TfZbPMQqE0

[Decision4Liver @Decision4Liver]

What we love about our General Assemblies: We get to receive quality #feedback, from our Scientific and Ethical Advisory Board Members Dr. #HermannMucke of @hmpharmacon, also on behalf of Prof. #DominiqueValla,

[HM PharmaConsultancy @hmpharmacon]

'International Drug Repurposing Patent Landscaping, Part 2: The Early Months of Covid-19' an article on #ScienceOpen: https://t.co/evubn6Byym

[HM PharmaConsultancy @hmpharmacon]

Patent highlights February–March 2024 https://t.co/NQkIYXZjiN

[Decision4Liver @Decision4Liver]

Next up: Work package presentations! 🧪 Selection and validation of combinatorial therapies using #preclinical rat models and set-up of #biomarkers of outcome and of companion diagnostics in patients’ samples. Presented by @UschnerFrank

#ACLF @MEDB_LAB @JonelTrebicka

[HM PharmaConsultancy @hmpharmacon]

@Decision4Liver @UschnerFrank @MEDB_LAB @JonelTrebicka

[. @gamonasterioo]

The value of ‘wasting time’ on deep thinking is often overlooked in a scientific ecosystem increasingly tainted by Wall Street’s productivity mindset.

https://t.co/hNTA74DNOr

[HM PharmaConsultancy @hmpharmacon]

In the inaugural issue of the new #ScienceOpen OA journal, #DrugRepurposing: #Patent Landscaping for #rarediseases 2010–2023
https://t.co/lqciO5EHKz

[ScienceOpen @Science_Open]

⭐️New Editor Spotlight on Hermann Mucke⭐️ Founder and CEO of @hmpharmacon, and a pivotal contributor to @REPO4EU, Mucke is a pioneer in #DrugRepurposing. Read more in our latest blog-post 👇 https://t.co/F71ab3saMs

[ScienceOpen @Science_Open]

@SDawsonBerlin @hhhwschmidt 💊 'Drug Repurposing: Then, Now, and in the Future' is an Honorary Lecture by Hermann Mucke of @hmpharmacon from Systems Medicine, AI, and Drug Repurposing (RExPO23), detailing the history and future potential of drug repurposing. https://t.co/PWICNw7zM9

[HM PharmaConsultancy @hmpharmacon]

#drugrepurposing #patent applications January–March 2024 https://t.co/cNcxTJYPKE

[HM PharmaConsultancy @hmpharmacon]

Just finished the final review with the EU Commission's #HADEA for our concluded #H2020 #drugrepurposing project, REPO-TRIAL (https://t.co/GVluRPdIus). We have already made a smooth transition to the much larger #HorizonEurope follow-up project, #REPO4EU (https://t.co/yrAQwOOPJr)

[Christopher Southan @cdsouthan]

One for the tractable proteome aficionados. Selects from the human Swiss-Prot cross-refs for chemistry (except Pharos under Miscellaneous)
Interesting but also slightly puzzling aspects (e.g. 47 Tchem not in ChEMBL) Note 132 BindingDB uniques may include patent-only targets